SEARCH:   Advanced

Blood, 1 November 2004, Vol. 104, No. 9, pp. 2976-2980. Prepublished online as a Blood First Edition Paper on July 13, 2004; DOI 10.1182/blood-2004-04-1674. This Article Full Text Full Text (PDF) All Versions of this Article: 2004-04-1674v1 104/9/2976    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Petersdorf, E. W. Articles by Hansen, J. A. Search for Related Content PubMed PubMed Citation Articles by Petersdorf, E. W. Articles by Hansen, J. A. Related Collections Immunobiology Neoplasia Transplantation Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  TRANSPLANTATION Limits of HLA mismatching in unrelated hematopoietic cell transplantation Effie W. Petersdorf, Claudio Anasetti, Paul J. Martin, Ted Gooley, Jerald Radich, Mari Malkki, Ann Woolfrey, Anajane Smith, Eric Mickelson, and John A. Hansen From the Division of Clinical Research, Fred Hutchinson Cancer Research Center; the H. Lee Moffitt Cancer Center and Research Institute; the Seattle Cancer Care Alliance; and the Department of Medicine, University of Washington School of Medicine, Seattle, WA. HLA matching between the donor and recipient improves the success of unrelated hematopoietic cell transplantation (HCT). Matched donors are available for only a minority of patients. Further information is needed to evaluate the limits of HLA mismatching. We examined the association of mortality with HLA-A, -B, -C, -DRB1, and -DQB1 mismatching in 948 patients who received a T-replete unrelated HCT for treatment of a marrow disorder. A single HLA allele or antigen mismatch was associated with increased mortality among patients with chronic myeloid leukemia (CML) within 2 years after diagnosis compared to patients with no HLA mismatch, but not among those with more advanced malignancy. In particular, a single HLA-C mismatch conferred increased risk of mortality compared to matches. There was a suggestion for increased mortality with multiple mismatches involving HLA-DQB1 compared to multiple mismatches not involving HLA-DQB1. Donors with a single HLA allele or antigen mismatch may be used for HCT when a fully matched donor is not available for patients with diseases that do not permit time for a lengthy search. Whenever possible, HLA-C mismatches should be avoided for patients with early stage CML, and HLA-DQB1 mismatches should be avoided for patients with multiple mismatches. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: S. J. Lee, J. Klein, M. Haagenson, L. A. Baxter-Lowe, D. L. Confer, M. Eapen, M. Fernandez-Vina, N. Flomenberg, M. Horowitz, C. K. Hurley, et al. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation Blood, December 15, 2007; 110(13): 4576 - 4583. [Abstract] [Full Text] [PDF] A. Schrauder, A. Reiter, H. Gadner, D. Niethammer, T. Klingebiel, B. Kremens, C. Peters, W. Ebell, M. Zimmermann, F. Niggli, et al. Superiority of Allogeneic Hematopoietic Stem-Cell Transplantation Compared With Chemotherapy Alone in High-Risk Childhood T-Cell Acute Lymphoblastic Leukemia: Results From ALL-BFM 90 and 95 J. Clin. Oncol., December 20, 2006; 24(36): 5742 - 5749. [Abstract] [Full Text] [PDF] I. Yakoub-Agha, F. Mesnil, M. Kuentz, J. M. Boiron, N. Ifrah, N. Milpied, S. Chehata, H. Esperou, J.-P. Vernant, M. Michallet, et al. Allogeneic Marrow Stem-Cell Transplantation From Human Leukocyte Antigen-Identical Siblings Versus Human Leukocyte Antigen-Allelic-Matched Unrelated Donors (10/10) in Patients With Standard-Risk Hematologic Malignancy: A Prospective Study From the French Society of Bone Marrow Transplantation and Cell Therapy J. Clin. Oncol., December 20, 2006; 24(36): 5695 - 5702. [Abstract] [Full Text] [PDF] W. M. Leisenring, P. J. Martin, E. W. Petersdorf, A. E. Regan, N. Aboulhosn, J. M. Stern, S. N. Aker, R. C. Salazar, and G. B. McDonald An acute graft-versus-host disease activity index to predict survival after hematopoietic cell transplantation with myeloablative conditioning regimens Blood, July 15, 2006; 108(2): 749 - 755. [Abstract] [Full Text] [PDF] J. F. Apperley Managing the Patient with Chronic Myeloid Leukemia Through and After Allogeneic Stem Cell Transplantation Hematology, January 1, 2006; 2006(1): 226 - 232. [Abstract] [Full Text] [PDF]

	Copyright © 2004 by American Society of Hematology         Online ISSN: 1528-0020